Announcements
Projects
Orgs
Project Post
Articles 4
Votes 0
Modernatx.com
Articles
4
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine - Moderna Investor Relations
16d
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), Demonstrated Superior Recurrence-Free Survival in Patients with High-Risk Stage III/IV Melano - Moderna Investor Relations
~2y
Moderna Announces Clinical and Program Updates at 4th Vaccines Day - Moderna Investor Relations
>2y
Moderna Announces Interim Phase 3 Safety and Immunogenicity Results for mRNA-1010, a Seasonal Influenza Vaccine Candidate - Moderna Investor Relations
>2y